Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.50 |
| ▸ | MAOB | P27338 | 4/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | PTGIR | P43119 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23295260 | 0.93 | MAOA (0.58) | MAOAMAOBCRBNDDB1AR | |
| SCHEMBL642608 | 0.91 | CRBN (0.47) | MAOAMAOBCRBNDDB1AR | |
| SCHEMBL23295277 | 0.83 | MAOA (0.65) | MAOAMAOBCRBNDDB1AR | |
| SCHEMBL2547361 | 0.81 | DDB1 (0.45) | MAOAMAOBCRBNDDB1PTGIR | |
| Hydrochloric Acid SCHEMBL2773983 | 0.79 | DDB1 (0.44) | MAOAMAOBCRBNDDB1PTGIR | |
| Hydrochloric Acid SCHEMBL10799877 | 0.78 | MAOA (0.43) | MAOAMAOBCRBNDDB1 | |
| SCHEMBL5005486 | 0.78 | CRBN (0.46) | MAOAMAOBCRBNDDB1NPC1 | |
| SCHEMBL13609520 | 0.77 | MAOA (0.50) | MAOAMAOBCRBNARPTGIR | |
| SCHEMBL15271173 | 0.77 | MAOA (0.50) | MAOAMAOBCRBNDDB1AR | |
| SCHEMBL4696488 | 0.76 | MAOA (0.48) | MAOAMAOBCRBNDDB1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109476628-A | Sulfonyl cyclic alkyl amides compound as TRPA1 regulator | 豪夫迈·罗氏有限公司 | 2019-03-15 | — | — | CN | disclosed |
| EP-2463283-B1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | PFIZER PROD INC (US) | 2014-06-11 | — | — | EP | disclosed |
| EP-2010520-B1 | HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PROD INC (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-2463283-A1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | Pfizer Products Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8119624-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110039821-A1 | Fused Phenyl Amido Heterocyclic Compounds | PFIZER INC | 2011-02-17 | — | — | US | disclosed |
| US-7842713-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC (US) | 2010-11-30 | — | — | US | disclosed |
| EP-1756076-B1 | HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2010-08-11 | — | — | EP | disclosed |
| EP-1756076-B1 | HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2010-08-11 | — | — | EP | disclosed |
| US-7745475-B2 | Such as 3-[(1S)-2-hydroxy-1-methylethoxy]-5-[4-(methylsulfonyl)phenoxy]-N-1,3-thiazol-2-ylbenzamide; glucokinases (Glk) | ASTRAZENECA AB (SE) | 2010-06-29 | — | — | US | disclosed |
| EP-2010520-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | Pfizer Products Incorporated (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-1992623-A1 | Heteroaryl benzamide derivative for use as GLK activator in the treatment of diabetes | Astra Zeneca AB (SE) | 2008-11-19 | — | — | EP | disclosed |
| EP-1992623-A1 | Heteroaryl benzamide derivative for use as GLK activator in the treatment of diabetes | Astra Zeneca AB (SE) | 2008-11-19 | — | — | EP | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080015203-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015203-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015203-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| WO-2007122482-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| EP-1756076-A1 | HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005121110-A1 | HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015203-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | GRK4, GRK5, GRK2 | MAOA 3858/4885MAOB 3695/4885CRBN 3707/4885 |
| US-20110039821-A1 | Fused Phenyl Amido Heterocyclic Compounds | GCK, GCKR, HK1 | MAOA 905/4885MAOB 914/4885CRBN 2704/4885 |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | GCK, GCKR, HK1 | MAOA 905/4885MAOB 914/4885CRBN 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.